Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24210733 | 0.82 | MAPT (0.43) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL2454697 | 0.82 | GSK3B (0.46) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL1529989 | 0.82 | MAPT (0.46) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL3581664 | 0.82 | MAPT (0.50) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL22692943 | 0.81 | CYP1A2 (0.49) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL17834830 | 0.80 | MAPT (0.53) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL397136 | 0.80 | MAPT (0.49) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL163725 | 0.80 | KDM4E (0.57) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL7914722 | 0.80 | MAPT (0.49) | MAPTPKMATMPOLBCYP1A2 | |
| SCHEMBL2987502 | 0.80 | MAPT (0.49) | MAPTPKMATMPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064558-A2 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 2002-08-22 | — | — | WO | claimed |
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2729455-B1 | BIARYL DERIVATIVES AS NACHR MODULATORS | LUPIN LTD (IN) | 2016-09-14 | — | — | EP | disclosed |
| EP-2729455-B1 | BIARYL DERIVATIVES AS NACHR MODULATORS | LUPIN LTD (IN) | 2016-09-14 | — | — | EP | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-8946432-B2 | Biaryl derivatives as nAChR modulators | LUPIN LIMITED (IN) | 2015-02-03 | — | — | US | disclosed |
| US-8946432-B2 | Biaryl derivatives as nAChR modulators | LUPIN LIMITED (IN) | 2015-02-03 | — | — | US | disclosed |
| US-20140155433-A1 | BIARYL DERIVATIVES AS NACHR MODULATORS | LUPIN LIMITED (IN) | 2014-06-05 | — | — | US | disclosed |
| US-20140155433-A1 | BIARYL DERIVATIVES AS NACHR MODULATORS | LUPIN LIMITED (IN) | 2014-06-05 | — | — | US | disclosed |
| EP-2729455-A1 | BIARYL DERIVATIVES AS NACHR MODULATORS | Lupin Limited (IN) | 2014-05-14 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| WO-2008098104-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2002064558-A2 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | MAPT 3584/4885PKM 146/4885ATM 112/4885 |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | MAPT 758/4885PKM 354/4885ATM 436/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | MAPT 1370/4885PKM 328/4885ATM 199/4885 |
| US-20140155433-A1 | BIARYL DERIVATIVES AS NACHR MODULATORS | CHRM2, CHRM1, CHRM5 | MAPT 330/4885PKM 2682/4885ATM 1857/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | MAPT 2963/4885PKM 152/4885ATM 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.